← Back to patent-cliff list
Butylidenephthalide
Tier C — Watch / tradeButylidenephthalide
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Natural product / extract
Type
Targets：AXL, NR4A1, Telomerase
Brand：Cerebraca wafer
Indications (approved)：Glioblastoma, Glioma, Amyotrophic lateral sclerosis
Regional status
US
Phase III
2026-01-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Butylidenephthalide?
Approved indications include: Glioblastoma, Glioma, Amyotrophic lateral sclerosis.
When does the Butylidenephthalide patent expire?
No public expiry year is available for Butylidenephthalide yet; this page updates once verified.
How do I get a quote for Butylidenephthalide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29